Serotonin 4 Receptor Agonist Composition for Psoriasis Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psoriasis, including topical and oral medications, biologics, and phototherapy, do not effectively utilize serotonin 4 receptor agonists for therapeutic or prophylactic purposes, despite their potential efficacy.
Innovation Solution
A therapeutic or prophylactic agent for psoriasis containing serotonin 4 receptor agonists such as mosapride, prucalopride, velusetrag, and their pharmaceutically acceptable salts, administered orally or parenterally, to treat or prevent psoriasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional psoriasis treatments (topical medications, oral medications, biologics, phototherapy) are used, then psoriasis symptoms can be managed, but the treatment options do not effectively utilize serotonin 4 receptor agonists which have shown potential efficacy in reducing psoriasis symptoms
Solution Approach 1:
The patent changes the pharmacological parameter by introducing serotonin 4 receptor agonists as a new class of treatment agents. This represents a fundamental shift in the mechanism of action from conventional treatments, leveraging the specific biological activity of serotonin 4 receptor stimulation to reduce psoriasis symptoms, thereby improving treatment effectiveness while maintaining diversity through this novel approach
2Reliability
If serotonin 4 receptor agonists are introduced as a new treatment class, then effectiveness in reducing psoriasis symptoms is improved, but the complexity of treatment guidelines and clinical application increases
Solution Approach 1:
The patent segments the treatment approach by providing specific guidance on serotonin 4 receptor agonist usage, including dosage considerations and patient selection criteria. This segmentation allows complex treatment protocols to be broken down into manageable components, making the integration of new treatment classes more systematic and less overwhelming for clinicians
3Adaptability or versatility
If multiple serotonin 4 receptor agonists are available (mosapride, prucalopride, velusetrag, tegaserod, cisapride, cinitapride, clebopride, felcisetrag, naronapride, usmarapride, relenopride, renzapride, CJ-033466, revexepride, E-3620), then treatment versatility is improved, but the difficulty of selecting the appropriate agent increases
Solution Approach 1:
The patent applies local quality by highlighting specific serotonin 4 receptor agonists with particular characteristics or suitability for different patient profiles. Instead of treating all agonists uniformly, the guidance distinguishes between agents based on their specific properties, making the selection process more straightforward by matching patient needs with appropriate agent characteristics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The agent significantly reduces psoriasis symptoms by suppressing auricular thickening in psoriasis model mice, demonstrating a remarkable effect in treating and preventing psoriasis.
Implementation Method 1
mosapride, which is widely used to improve gastrointestinal symptoms due to its gastroprokinetic action
Implementation Method 2
The agent significantly reduces psoriasis symptoms by suppressing auricular thickening in psoriasis model mice
Data Source
AI summary
The present invention provides a novel therapeutic or prophylactic agent for psoriasis. This therapeutic or prophylactic agent for psoriasis contains a serotonin 4 receptor agonist.